Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

Sandanayake, Neomal S.; Camuzeaux, Stéphane; Sinclair, John; Blyuss, Oleg; Andreola, Fausto; Chapman, Michael H.; Webster, George; Smith, Ross C.; Timms, John F.; Pereira, Stephen P.

doi:10.1186/1472-6890-14-7

Cited by 19 publications

(17 citation statements)

References 38 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For serum samples pretreated with magnetic beads, the highest discrimination quality (AUC: 0.87) was shown by a peptide with a mass of 2120.29 Da, whereas using ZipTips allowed reaching an AUC of 0.9 for a peptide mass of 1277.49 Da. The sensitivities and specificities of the discrimination quality of peaks obtained in our study were satisfactory in all sample enrichment strategies used according to the data presented in the available literature [ 20 , 31 , 32 ].…”

Section: Resultssupporting

confidence: 66%

Influence of Honeybee Sting on Peptidome Profile in Human Serum

Matysiak

Światły

Hajduk

et al. 2015

Toxins

View full text Add to dashboard Cite

The aim of this study was to explore the serum peptide profiles from honeybee stung and non-stung individuals. Two groups of serum samples obtained from 27 beekeepers were included in our study. The first group of samples was collected within 3 h after a bee sting (stung beekeepers), and the samples were collected from the same person a second time after at least six weeks after the last bee sting (non-stung beekeepers). Peptide profile spectra were determined using MALDI-TOF mass spectrometry combined with Omix, ZipTips and magnetic beads based on weak-cation exchange (MB-WCX) enrichment strategies in the mass range of 1–10 kDa. The samples were classified, and discriminative models were established by using the quick classifier, genetic algorithm and supervised neural network algorithms. All of the statistical algorithms used in this study allow distinguishing analyzed groups with high statistical significance, which confirms the influence of honeybee sting on the serum peptidome profile. The results of this study may broaden the understanding of the human organism’s response to honeybee venom. Due to the fact that our pilot study was carried out on relatively small datasets, it is necessary to conduct further proteomic research of the response to honeybee sting on a larger group of samples.

show abstract

Section: Resultssupporting

confidence: 66%

Influence of Honeybee Sting on Peptidome Profile in Human Serum

Matysiak

Światły

Hajduk

et al. 2015

Toxins

View full text Add to dashboard Cite

show abstract

“…The use of MALDI-TOF-MS profiling enables to obtain a whole pattern of low-molecular weight proteins occurring in human serum and was indicated as a promising strategy in several cancer research. This technology was found to be effective in discrimination of healthy individuals from patients with various tumors such as biliary tract cancer [ 32 ], gastric cancer [ 33 ], prostate cancer [ 34 ], ovarian cancer [ 16 ] and head and neck cancer [ 35 ]. Moreover, serum peptidome features were suggested to be useful in monitoring the toxicity of applied therapy in women with breast cancer [ 36 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer

Klupczynska

Światły

Hajduk

et al. 2016

IJMS

View full text Add to dashboard Cite

Due to high mortality rates of lung cancer, there is a need for identification of new, clinically useful markers, which improve detection of this tumor in early stage of disease. In the current study, serum peptide profiling was evaluated as a diagnostic tool for non-small cell lung cancer patients. The combination of the ZipTip technology with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for the analysis of peptide pattern of cancer patients (n = 153) and control subjects (n = 63) was presented for the first time. Based on the observed significant differences between cancer patients and control subjects, the classification model was created, which allowed for accurate group discrimination. The model turned out to be robust enough to discriminate a new validation set of samples with satisfactory sensitivity and specificity. Two peptides from the diagnostic pattern for non-small cell lung cancer (NSCLC) were identified as fragments of C3 and fibrinogen α chain. Since ELISA test did not confirm significant differences in the expression of complement component C3, further study will involve a quantitative approach to prove clinical utility of the other proteins from the proposed multi-peptide cancer signature.

show abstract

“…Although EGFR mutation was a promising predictor of response to EGFR-TKIs treatment, many unfavorable conditions limited its usage. At present, some attempts have been taken to replace tissue specimens with blood, pleural effusion or other substitute samples that may contain tumor information for the detection of EGFR mutations (13,15,30). However, a more constructive attempt is to establish a new predictor system using proteomic techniques.…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, there is an urgent need to develop specific biomarkers in specimens that are more easily assessable, such as serum or plasma. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) is a soft ionization technique used in mass spectrometry, which allows the analysis of biomolecules (biopolymers such as DNA, proteins, peptides and sugars) and large organic molecules (such as polymers, dendrimers and other macromolecules), which tend to be fragile and fragment when ionized by more conventional ionization methods (15,16). MALDI-TOF MS is a high-throughput procedure and much faster, more accurate and cheaper compared with other techniques based on immunological or biochemical tests (17,18).…”

Section: Introductionmentioning

confidence: 99%

Serum peptide expression and treatment responses in patients with advanced non‑small‑cell lung cancer

Tang

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Epidermal growth factor receptor (EGFR) mutation is an important predictor for response to personalized treatments of patients with advanced non-small-cell lung cancer (NSCLC). However its usage is limited due to the difficult of obtaining tissue specimens. A novel prediction system using matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has been reported to be a perspective tool in European countries to identify patients who are likely to benefit from EGFR tyrosine kinase inhibitor (TKI) treatment. In the present study, MALDI-TOF MS was used on pretreatment serum samples of patients with advanced non-small-cell lung cancer to discriminate the spectra between disease control and disease progression groups in one cohort of Chinese patients. The candidate features for classification were subsequently validated in a blinded fashion in another set of patients. The correlation between plasma EGFR mutation status and the intensities of representative spectra for classification was evaluated. A total of 103 patients that were treated with EGFR-TKIs were included. It was determined that 8 polypeptides peaks were significant different between the disease control and disease progression group. A total of 6 polypeptides were established in the classification algorithm. The sensitivity of the algorithm to predict treatment responses was 76.2% (16/21) and the specificity was 81.8% (18/22). The accuracy rate of the algorithm was 79.1% (34/43). A total of 3 polypeptides were significantly correlated with EGFR mutations (P=0.04, P=0.03 and P=0.04, respectively). The present study confirmed that MALDI-TOF MS analysis can be used to predict responses to EGFR-TKI treatment of the Asian population where the EGFR mutation status differs from the European population. Furthermore, the expression intensities of the three polypeptides in the classification model were associated with EGFR mutation. IntroductionLung cancer remains a common cause of mortalities worldwide, accounting for 1.6 million mortalities in 2012 and ~20% of all cancer mortalities (1). Non-small cell lung cancer (NSCLC) is the predominant type of the disease with ~80% of cases (1). In the last decade, the important discovery of mutations in the epidermal growth factor receptor (EGFR) gene had led to the development of targeted therapy and personalized medicine (2). One class of anti-tumor drugs that target EGFR is a group of small molecule inhibitors that inhibit the tyrosine kinase domain of EGFR, EGFR-tyrosine kinase inhibitors (TKIs). Examples of EGFR-TKIs include gefitinib and erlotinib (3,4).EGFR-TKIs have demonstrated initial success in some patients with activating mutations (5). However, numerous patients do not respond to the drug (6-8). Therefore, the identification of biomarkers that are predicative of response to the drug became a key issue for doctors to select the optimal therapy. To date, mutations in the EGFR gene (exon 19 deletion, exon 18 G719X and exon 21 L858R) have been reported to be predictors ...

show abstract

Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

Cited by 19 publications

References 38 publications

Influence of Honeybee Sting on Peptidome Profile in Human Serum

Influence of Honeybee Sting on Peptidome Profile in Human Serum

Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer

Serum peptide expression and treatment responses in patients with advanced non‑small‑cell lung cancer

Contact Info

Product

Resources

About